Global Advanced Therapy Drugs (ATMP) Market to 2028: Focus on CAR-T, Gene, Cell and Stem Cell Therapy

DUBLIN, September 22, 2021– (COMMERCIAL THREAD)–The “Global Advanced Therapy Drugs Market 2021-2028” report was added to offer.

The global advanced therapy drugs market size is expected to reach USD 21.2 billion by 2028. The market is expected to grow at a CAGR of 13.2% from 2021 to 2028.

ATMPs (Advanced Therapy Medicinal Products) have the potential to cure diseases by addressing their root causes rather than symptomatic treatment. Thus, ATMPs help deliver transformative benefits that are not offered by conventional treatments. These factors are expected to drive the market over the forecast period.

The groundbreaking approvals of Tecartus and Abecma after the approval of Zolgensma, Kymriah and Yescarta have reinforced the exceptional advances in this space. These approvals have boosted the flow of investments in this area, resulting in revenue growth. Key companies adopt various business models to speed up the process of manufacturing products.

In addition, the market has seen several acquisitions by players who intended to enter or expand their existing businesses in this area. The acquisitions of Kite Pharma by Gilead Life Science, AveXis by Novartis and Juno Therapeutics by Celgene are some major and recent examples. These acquisitions illustrate the growing interest of well-established pharmaceutical companies in this market. Growing competition for gene therapy buybacks can result in high premiums.

On the other hand, with increasing consumer demands, ATMP manufacturers are outsourcing the manufacturing of their products, thus creating lucrative opportunities for contract manufacturing organizations. Thus, several CDMOs have extended their facilities.

For example, in January 2021, FUJIFILM Diosynth Biotechnologies invested USD 40 million to set up a new process development and manufacturing facility for advanced therapies and viral vectors.

Highlights of the Advanced Therapy Drugs Market Report

  • Cell therapy segment accounted for the largest share of revenue in 2020 due to the presence of a high number of approved products in this segment

  • Increased investment flows to sponsor clinical trials also boosted the revenue share of cell therapy segment.

  • Introduction of effective guidelines to support cell therapy manufacturing and recent approval of advanced therapies further contribute to segment dominance

  • The geographic expansion of Yescarta and Kymriah in Japan and Europe has prompted investors to support development in this space

  • Recent Gene Therapy Approvals Have Drastically Speeded Up Clinical Trials In This Segment

  • COVID-19 pandemic has opened up new areas for key players to invest in T cell research for viral infections

  • Research Community Actively Evaluates Potential of Advanced Therapies in COVID-19 Patients, Contributing to Market Growth

  • North America accounted for largest share of revenue in 2020 due to exponential rise in clinical trials of advanced therapies

  • Strong ATMP pipeline in the United States accelerated revenue generation in the region

  • In addition, the shift in focus of US-based companies from conventional drug development towards ATMPS is driving regional growth.

  • In Asia-Pacific, the market is expected to experience the fastest CAGR due to the expansion of ATMP landscape in emerging markets such as China at the forefront

  • Expansion of business of China-based CDMOs has boosted regional market growth

  • Key companies undertake various strategic initiatives to maintain their position in the market. The collaboration between ViGeneron GmbH and Biogen Inc. in January 2021 is one of the notable examples of collaboration in this space.

  • The companies collaborated on the development of an AAV-based gene therapy product for the treatment of inherited eye diseases

Market variables, trends and scope

Market dynamics

Market driver analysis

  • Advantages over conventional therapies

  • Growing competition between market players

  • Increased number of clinical trials for ATMP

Analysis of market restrictions

Analysis of market opportunities

  • Increased funding for gene and cell therapy

  • Extension of facilities for cell and gene therapy

  • Technological Advances in Manufacturing Vectors

Analysis of market challenges

Regulatory landscape, by geography

Payment and pricing models

Patent landscape

Transactions, financing, partnerships and collaborations

Pipeline analysis

Case study

COVID-19 impact assessment

Analysis of challenges

Opportunity analysis

Challenges in making T cell therapies against COVID-19

Analysis of clinical trials

Key market initiatives


Companies mentioned

  • F. Hoffmann-La Roche Ltée.

  • Bluebird Bio, Inc.

  • Novartis AG

  • UniQure SA

  • Bristol-Myers Squibb Company

  • Gilead Life Sciences, Inc.

  • Kolon TissueGene, Inc.

  • JCR Pharmaceuticals Co., Ltd.


  • Vericel Corporation

  • PHARMICELL Co., Ltd.

  • Organogenesis Inc.

For more information on this report, visit

See the source version on

Laura Wood, Senior Press Director
[email protected]

For EST office hours, call 1-917-300-0470
For USA / CAN call toll free 1-800-526-8630
For GMT office hours, call + 353-1-416-8900

Source link

About Johnnie Gross

Johnnie Gross

Check Also

Revalie Ottawa opens its doors to a new benchmark in student life

OTTAWA, ON, October 16, 2021 / CNW / – Mayor of Ottawa Jim watson and …

Leave a Reply

Your email address will not be published. Required fields are marked *